Reference

1. Tipton MC. Susruta of India is an unrecognized contributor to the history of exercise physiology. J Appl Physiol, 2008; 108: 1553–6.
2. Abdul-Ghani MA, DeFronzo RA. Dapaglifl ozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2013;14(12):1695-703.
3. The History of Diabetes. From Ritu Lakhtakiya 3rd JUN 13.369.
4. Kumar CR. Basic Pathology, Prism PVT. Limited Bangalore, 5th edition, 1992, 569-587.
5. Wassmuth R, Lernmark A. The genetics of susceptibility to diabetes, ClinImmunol, Immunopathol. 1989; 53:358- 399,
6. Maria J. Meneses, Branca M. Silva, Antidiabetes Drugs: Mechanism of action and Potential outcomes on cellular metabolism.Current Pharmaceutical Design, 2015; vol. 21, No. 25 3607.
7. Deborah, W. and Ncrna, R. (2019) Insulin Charts. Written by Heather Grey—Updated on March 4, 2019.https: //www.healthline.com/health/type-2-diabetes/insulin-chart.
8. Villa, C., Pan, D., Zaitsev, S., Cines, D., Siegel, D.andMuzykantov, V. (2015) Delivery od Drugs Bound to Erythrocytes: New Avenues for an Old Intravascular Carrier. Therapeutic Delivery, 6,795-826.https: //doi.org/10.4155/tde.15.34.
9. K. D. Tripathi, “Essentials of Medical Pharmacology,” 5th Edition, Jaypee Brothers Medical Publishers (P) LTD, New Delhi, 2003.
10. S.Y. Tan, J.L. Mei Wong, Y.J. Sim, S.S. Wong, S.A. Mohamed Elhassan, S.H. Tan, G.P. Ling Lim, N.W. Rong Tay, N.C. Annan, S.K. Bhattamisra, M. Candasamy, Type 1 and 2 diabetes mellitus: a review on the current treatment approach and gene therapy as potential intervention, Diabetes Metab. Syndr. Clin. Res. Rev. 13.
11. K. D. Tripathi, “Essentials of Medical Pharmacology,” 5th Edition, Jaypee Brothers Medical Publishers (P) LTD, New Delhi, 2003.
12. Maria J. Meneses, Branca M. Silva, Antidiabetes Drugs: Mechanism of action and Potential outcomes on cellular metabolism.Current Pharmaceutical Design, 2015; vol. 21, No. 25 3607.
13. Furqan UI Haq, AbuzarSiraj, Tanveer Hamid. Comparative review of drugs used in Diabetes mellitus- new and old. Journal of diabetes mellitus Vol. 11 No. 4, November 2021
14. Tao, L., Vikas, B. and Matthew, S. (2021) First Aid for the USMLE Step 1 2021. 31st Edition, McGraw-Hill Education, New York, 352-353.
15. Mcfarthing, Larson, D. and Simuni, T. (2020) Clinical Trail Highlits- GLP-1Agonist, Journal of Parkinsons Disease, 10: 355-368. https: //doi.org/10.3233/JPD-200002.
16. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastrienterology, 2007; 132: 2131-57.
17. Bell, D. S., O‘Keefe, J. H. and Jellinge, P. (2008) Postprandial Dysmetabolism: The Missing Link between Diabetes and Cardiovascular Events? Endocrine Practice, 14: 112- 124.
18. Ceppa, E. P., Ceppa, D. P., Omotosho, P. A., D ickerson 2nd., J. A., Park, C. W. and Portenier, D. D. (2012) Algorithm to DaignoseEtiology of Hypoglycemia after Roux-en-Y Gastric Bypass for Morbid Obesity: Case Series and Review of the Literature. Surgery for the Obesity and Related Disease, 8, 641-647.2011. 08. 008.
19. Reuser, A. J. and Wisselaar, H. A. (1994) An Evaluation of the Potential Side Effects of Alpha-Glucosidase Inhibitors Used for the Management of Diabetes Mellitus. European Journal of Clinical Investigation, 24: 19-24. https: //doi.org/10.1111/j.1365- 2362.1994.tb02251.x
20. Ahren, B. (2009) Clinical Results of Treating Type 2 Diabetes Patients with Sitagliptin, Vildagliptin or Saxagliptin-Diabetes Control and Potential Adverse Events. Best Practice and Research Clinical Endocrinology and Metabolism, 23: 487-498.
21. Thornberry, N. A. and Gallwitz, B. (2009) Mechanism of action of inhibitors of DPP-4. Best Practice and Research Clinical Endocrinology and Metabolism, 23: 479-486.https: //doi.org/10.1016/j.beem.2009.03.004.
22. Tominaga M, Igarashi M, Diamon M, et al. Thiazolidinediones (AD – 4833 and CS – 045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocr J, 1993; 40: 343-9.
23. Gitlin N, Julie NL, Spurr CL, et al. Two cases of severe clinical and histological hepatotoxic associated with troglitazone. Ann In- term Med, 1998; 129: 36-38.
24. Ahmadian M, Suh JM, H ah N, et al. PPAR gamma signaling and metabolism; the good, the bad, and future. Nat Med, 2013; 19: 557-66.
25. R.W. Nesto, D. Bell, R. O. Bonow, V. Fonseca, S. M. Grundy, E. S. Horton, M. L. Winter, D. Porte, C.F. Semenkovich, S. Smith, L. H. Young and R. Kahn, Circulation,
26. Standl, E., Schernthaner, G., Rybka, J., Hanefeld, M., Raptis, S. A. and Naitch, L. ( 2001) Improved Glycaemic control with Miglitol in Inadequately- controlled Type 2 Diabetes. Diabetes Research and Clinical Practices, 51: 205- 213.
27. Chasis H, Jolliffe N, Smith HW: The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine, and urea by man. J Clin Invest, 1933; 12: 1083–1090. 10.1172/JCI100559.
28. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA: Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest, 79: 1510–1515, 1987. 10.1172/JCI112981.
29. Grempler R., Thomas L., Eckhardt M., Himmelsbach F., Sauer A., Sharp D.E., Bakker R.A., Mark M., Klein T., Eickelmann P. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes. Metab, 2012; 14: 83–90.
30. R. K. Crane, D. Miller, and I. Bihler, in Membrane transport and metabolism, ed. A. Kleinzeller and A. Kotyk, Academic Press, New York, 1961; pp. 439–449
31. OMIM182380, Solute carrier family-5 (sodium/glucose cotransporter), member1, SLC5A1, https: //www.omim.org/entry/182380, accessed April 2019; (b) E. M. Wright and E. Turk, Eur. J. Physiol, 2004; 447: 510–518.
32. J. J. Neumiller, J. R. White and R. K. Campbell, Drugs, 2010; 70: 377–385.
33. OMIM182380, Solute carrier family-5 (sodium/glucose cotransporter), member1, SLC5A1, https: //www.omim.org/entry/182380, accessed April 2019; (b) E. M. Wright and E. Turk, Eur. J. Physiol, 2004; 447: 510–518. (c) A. Diez-Sampedro, B. A. Hirayama, C. Osswald, V. Gorboulev, K. Baumgarten, C. Volk, E. M. Wright and H. Koepsell, Proc. Natl. Acad. Sci. U. S. A, 2003; 100: 11753– 11758
34. https://www.jbc.org/article/S0021-9258(17)49780-8/fulltext
35. David L, Joffe, BSpharm.LDE, FACA SGLT2 inhibitors: A New Class of Diabetes Medication Sep 19, 2018
36.  (a) E. M. Wright, Am. J. Physiol. Renal. Physiol., 2001, 280, F10–F18 (b) E. M. Wright, G. M. Martin, and E. Turk, in Familial glucose–galactose malabsorption and hereditary renal glycosuria, ed. C. R. Scriver, A. L. Beaudet, W. S. Sly and D. Valle, McGrow-Hill, New York, 8th ed, 2001, Metabolic basis of inherited disease, 4891–4908.         
37. Ana Diez- Sampedro, BruceA, Hirayana, ChristinaOsswald., VelentinGorboulev glucose sensor hiding in a family of transporters Sep. 16, 2003
38. ERNEST M. WRIGHT; Genetic disorder of membrane Transport I.GGM. Physiology Department University of California school of medicine, Los Angeles, California 90095- 175 G. 879-88039.
39. S. Faham, A. Watanabe, G. M. Besserer, D. Cascio, A. Specht, B. A. Hirayama, E. M. Wright and J. Abramson, Science, 2008; 321: 810–814.
40. Rahul P. Kshirsagar, Abhishek A. Kulkarni, Rashmi S. Chouthe. SGLT inhibitors as antidiabetes agents: a comprehensive review. 9th Jan 2020; 10: 1733-1756.
41.  (a) D. D. F. Loo, B. A. Hirayama, A. K. Meinild, G. Chandy, Z. Zeuthen and E. M. Wright, J. Physiol, 1999; 518: 195–202 (b) A. C. Schoolwerth, B. C. Smith and R. M. Culpepper, Miner. Electrolyte Metab, 1988; 14: 347–361
42. (a) G. A. Quamme and H. J. Freeman, Am. J. Physiol, 1987; 253: F151–F157 (b) A. Mather and C. Pollock, Kidney Int, 2011; 79: S1–S6.
43. HaroonJakher, T. Chang,K. Mahaffey Canagliflozin review - safety and efficacy profile in patients with T2DM. 1 Feb 2019